Abstract: The present invention provides compositions and methods for treating KMA-expressing malignancies including chimeric antigen receptors (CARs) and T cells containing CARs (CAR T-cells). The invention also provides methods and compositions comprising CAR T-cells co-expressing other anti-tumoral agents including cytokines and antibodies.

Abstract: The present invention provides compositions and methods for treating KMA-expressing malignancies including chimeric antigen receptors (CARs) and T cells containing CARs (CAR T-cells). The invention also provides methods and compositions comprising CAR T-cells co-expressing other anti-tumoral agents including cytokines and antibodies.

Abstract: The present disclosure relates generally to promoters derived from the AAV anti-sense strand, their use in the expression of one or more heterologous coding sequences, and isolated polynucleotides, vectors and recombinant viruses comprising the promoters. The present disclosure also relates to enhancers derived from the AAV anti-sense strand, their use in increasing the expression of one or more heterologous coding sequences, and isolated polynucleotides, vectors and recombinant viruses comprising the enhancers.

Abstract: The present invention provides compositions and methods for treating KMA-expressing malignancies including chimeric antigen receptors (CARs) and T cells containing CARs (CAR T-cells). The invention also provides methods and compositions comprising CAR T-cells co-expressing other anti-tumoral agents including cytokines and antibodies.

Abstract: The present disclosure relates generally to promoters derived from the AAV anti-sense strand, their use in the expression of one or more heterologous coding sequences, and isolated polynucleotides, vectors and recombinant viruses comprising the promoters. The present disclosure also relates to enhancers derived from the AAV anti-sense strand, their use in increasing the expression of one or more heterologous coding sequences, and isolated polynucleotides, vectors and recombinant viruses comprising the enhancers.

Abstract: A sanitary diaper changing kit includes a package, a pair of disposable gloves in the package, and a re-sealable disposal bag in the package. Alternatively, the kit may include other materials such as small single-use package of moist wipes or towelettes, a small single-use package of antiseptic wipes, a small single use package of petroleum jelly and a small single-use package of powder. The sanitary diaper changing kit may be packaged and sold with a disposable diaper, or may be sold separately from diapers to be used in conjunction with a disposable diaper. The kit allows the person changing the diaper to be isolated from the contaminated diaper during the diaper changing operation and provides a convenient means by which the soiled diaper and other used or soiled materials may be disposed of in a sanitary procedure and diaper wearer remains isolated from care giver.